Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Antagonism of Nav channels and α1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine

Abstract : Ranolazine is a recently developed drug used for the treatment of patients with chronic stable angina. It is a selective inhibitor of the persistent cardiac Na+ current (INa) and is known to reduce the Na+-dependent Ca2+ overload that occurs in cardiomyocytes during ischemia. Vascular effects of ranolazine, such as vasorelaxation,have been reported and may involve multiple pathways. As voltage-gated Na+ channels (Nav) present in arteries play a role in contraction, we hypothesized that ranolazine could target these channels. We studied the effects of ranolazine in vitro on cultured aortic smooth muscle cells (SMC) and ex vivo on rat aortas in conditions known to specifically activate or promote INa. We observed that in the presence of the Nav channel agonist veratridine, ranolazine inhibited INa and intracellular Ca2+ calcium increase in SMC and arterial vasoconstriction. In arterial SMC, ranolazine inhibited the activity of tetrodotoxin-sensitive voltage-gated Nav channels and thus antagonized contraction promoted by low KCl depolarization. Furthermore, the vasorelaxant effects of ranolazine, also observed in human arteries and independent of the endothelium, involved antagonization of the α1-adrenergic receptor. Combined α1-adrenergic antagonization and inhibition of SMCs Nav channels could be involved in the vascular effects of ranolazine.
Liste complète des métadonnées

Littérature citée [52 références]  Voir  Masquer  Télécharger
Contributeur : Dominique Mornet <>
Soumis le : mercredi 15 avril 2020 - 11:12:28
Dernière modification le : jeudi 16 avril 2020 - 11:39:20


Virsolvy et al - 2015.pdf
Fichiers éditeurs autorisés sur une archive ouverte




Anne Virsolvy, Charlotte Farah, Nolwenn Pertuit, Lingyan Kong, Alain Lacampagne, et al.. Antagonism of Nav channels and α1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine. Scientific Reports, Nature Publishing Group, 2015, 5, pp.17969. ⟨10.1038/srep17969⟩. ⟨hal-01759003⟩



Consultations de la notice


Téléchargements de fichiers